시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
구속성 펩타이드 의약품 시장 보고서(2025년)
Constrained Peptide Drugs Global Market Report 2025
상품코드 : 1764291
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,501,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,396,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,292,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

구속성 펩타이드 의약품 시장 규모는 향후 수년간 급성장할 것으로 예측됩니다. 치료 및 맞춤형 치료에 대한 수요 증가, 구속 펩타이드의 결합 친화성과 세포에의 흡수 개선, 펩타이드 연구에 대한 정부·민간 투자 증가, 합성 구속 기술의 진보, 종양학이나 대사성 질환에 있어서의 응용 범위의 확대 등에 기인한다고 생각됩니다. 예측 기간 중에 예상되는 주요 동향에는 고상과 마이크로파 지원 펩타이드 합성의 진전, 펩타이드의 스테이플링법과 대환상화법의 개발, 펩타이드 설계에 있어서의 인공지능과 머신러닝의 통합, 서스테인블 펩타이드 생산을 위한 그린 케미스트리의 채용 등이 있습니다.

표적 치료에 대한 수요 증가가 향후 몇 년간의 구속성 펩타이드 의약품 시장의 성장을 견인할 것으로 예측됩니다. 이러한 수요 증가는 기존 치료법에 비해 정밀도가 높고 부작용이 적기 때문입니다. 제약 펩타이드는 약물 효과를 높이는 동시에 부작용을 최소화하여 복잡한 질병을 치료하는 표적 접근법의 강력한 후보로 자리매김하고 있습니다. 예를 들어, 2024년 12월 미국 비영리 의료 및 과학 단체인 미국 유전자 및 세포 치료학회(ASGCT)는 미국 식품의약국(FDA)이 2023년에 승인한 유전자 치료 제품이 2022년의 5개에서 6개로 증가했다고 보고했습니다.

구속성 펩타이드 의약품 시장의 주요 기업은 생체 이용률을 높이고 환자의 규정 준수를 향상시키고 이전에 치료할 수 없었던 병리학을 해결하기 위해 경구 거대 고리 펩타이드와 같은 고급 약물전달 이 솔루션의 개발에 주력하고 있습니다. 경구 대환상 펩타이드는 주사와는 대조적으로 경구 투여 시 안정성을 유지하고 효과적으로 흡수되도록 특별히 설계된 환상 펩타이드 기반 약물입니다. 2024년 2월, 미국의 생명공학 기업인 Insamo가 경구 환상 펩타이드를 발표했습니다. 인사모 플랫폼은 머신러닝에 의한 분자 설계, 초고 처리량 분자 생물학, 병렬 합성 화학을 채택하여 어려운 약물 표적이라도 원하는 약리학적 특성을 가진 전임상 후보 화합물을 신속하게 확인합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

KTH
영문 목차

영문목차

Constrained peptide drugs are peptides that have been chemically modified to maintain a fixed, stable three-dimensional shape, often achieved through cyclization or the introduction of chemical bridges. This structural constraint enhances their stability, improves binding affinity, and increases specificity for target proteins. The primary goal of constrained peptide drugs is to boost therapeutic effectiveness by making them more resistant to degradation and improving their selectivity compared to linear peptides.

The main types of constrained peptide drugs include linear peptides, cyclic peptides, stapled peptides, and multivalent peptides. Linear peptides consist of amino acid chains arranged in a straight, unbranched sequence without any cyclic or cross-linked structures. These drugs can be administered via various routes such as injectable, intranasal, transdermal, and oral methods. Their applications span across hospitals, biological research institutes, and other healthcare settings. Distribution channels include direct sales, third-party distributors, online pharmacies, and retail pharmacies. The end users of these drugs primarily include hospitals, pharmaceutical companies, research laboratories, and specialty clinics.

The constrained peptide drugs market research report is one of a series of new reports from The Business Research Company that provides constrained peptide drugs market statistics, including constrained peptide drugs industry global market size, regional shares, competitors with a constrained peptide drugs market share, constrained peptide drugs market segments, market trends and opportunities, and any further data you may need to thrive in the constrained peptide drugs industry. This constrained peptide drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The constrained peptide drugs market size has grown rapidly in recent years. It will grow from $2.79 billion in 2024 to $3.27 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth during the historic period can be credited to the rising prevalence of chronic diseases, growing demand for targeted therapies, advancements in drug delivery systems, improved peptide stability through chemical modifications, and regulatory backing for innovative therapeutics.

The constrained peptide drugs market size is expected to see rapid growth in the next few years. It will grow to $6.13 billion in 2029 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to the rising demand for targeted and personalized therapies, improved binding affinity and cellular uptake of constrained peptides, increasing government and private investments in peptide research, advancements in synthetic constraining techniques, and the widening scope of applications in oncology and metabolic disorders. Key trends expected during the forecast period include progress in solid-phase and microwave-assisted peptide synthesis, the development of peptide stapling and macrocyclization methods, the integration of artificial intelligence and machine learning in peptide design, the adoption of green chemistry for sustainable peptide production, and the use of peptide-protein conjugates and cell-penetrating peptides.

The rising demand for targeted therapies is anticipated to drive the growth of the constrained peptide drugs market in the coming years. Targeted therapies are medical treatments designed to specifically interact with molecular pathways responsible for the development and progression of diseases. This growing demand stems from their greater precision and fewer side effects compared to traditional treatments. Targeted therapies support the development of constrained peptide drugs by honing in on specific molecular mechanisms, thereby enhancing treatment accuracy. They increase drug effectiveness while minimizing adverse effects, positioning constrained peptides as strong candidates for targeted approaches in treating complex diseases. For example, in December 2024, the American Society of Gene & Cell Therapy (ASGCT), a U.S.-based non-profit medical and scientific organization, reported that the Food and Drug Administration (FDA) approved six gene therapy products in 2023, an increase from five in 2022. Hence, the growing demand for targeted therapies is fueling the expansion of the constrained peptide drugs market.

Leading companies in the constrained peptide drugs market are concentrating on developing advanced drug delivery solutions, such as oral macrocyclic peptides, to enhance bioavailability, boost patient compliance, and address previously untreatable conditions. Oral macrocyclic peptides are cyclic peptide-based drugs specifically designed to remain stable and be effectively absorbed when administered orally, as opposed to injections. For example, in February 2024, Insamo, a U.S.-based biotechnology firm, introduced oral cyclic peptides. These peptides are membrane-permeable and orally available, combining the high specificity of biologics with the convenience of oral delivery. Insamo's platform employs machine learning-guided molecular design, ultra-high-throughput molecular biology, and parallel synthetic chemistry to swiftly identify preclinical candidates with desirable pharmacological properties, even for difficult drug targets.

In March 2023, Ono Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan, partnered with PeptiDream Inc. to discover and develop new macrocyclic constrained peptide drugs. This collaboration seeks to utilize PeptiDream's proprietary Peptide Discovery Platform System (PDPS) to create high-affinity macrocyclic peptides aimed at challenging protein-protein interactions for novel drug development. PeptiDream Inc. is a Japan-based biotechnology firm specializing in the discovery and development of constrained peptide drugs.

Major players in the constrained peptide drugs market are AstraZeneca PLC, Novartis AG, Union Chimique Belge S.A. (UCB), CPC Scientific Inc., PeptiDream Inc., Protagonist Therapeutics Inc., Bicycle Therapeutics plc, Zealand Pharma A/S, Bio-Synthesis Inc., Encycle Therapeutics Inc., Circle Pharma Inc., Issar Pharmaceuticals Inc., Aileron Therapeutics Inc., Creative Peptides, Fierce Biotech, Lisata Therapeutics Inc., Pepscan Therapeutics B.V., Phylogica Ltd., Pepticom Ltd, and Spexis AG.

North America was the largest region in the constrained peptide drugs market in 2024. The regions covered in constrained peptide drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the constrained peptide drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The constrained peptide drugs market consists of sales of stapled peptides, modified peptide hormone analogs and cyclotides, and engineered natural peptides. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that businesses gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Constrained Peptide Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on constrained peptide drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for constrained peptide drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The constrained peptide drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Constrained Peptide Drugs Market Characteristics

3. Constrained Peptide Drugs Market Trends And Strategies

4. Constrained Peptide Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Constrained Peptide Drugs Growth Analysis And Strategic Analysis Framework

6. Constrained Peptide Drugs Market Segmentation

7. Constrained Peptide Drugs Market Regional And Country Analysis

8. Asia-Pacific Constrained Peptide Drugs Market

9. China Constrained Peptide Drugs Market

10. India Constrained Peptide Drugs Market

11. Japan Constrained Peptide Drugs Market

12. Australia Constrained Peptide Drugs Market

13. Indonesia Constrained Peptide Drugs Market

14. South Korea Constrained Peptide Drugs Market

15. Western Europe Constrained Peptide Drugs Market

16. UK Constrained Peptide Drugs Market

17. Germany Constrained Peptide Drugs Market

18. France Constrained Peptide Drugs Market

19. Italy Constrained Peptide Drugs Market

20. Spain Constrained Peptide Drugs Market

21. Eastern Europe Constrained Peptide Drugs Market

22. Russia Constrained Peptide Drugs Market

23. North America Constrained Peptide Drugs Market

24. USA Constrained Peptide Drugs Market

25. Canada Constrained Peptide Drugs Market

26. South America Constrained Peptide Drugs Market

27. Brazil Constrained Peptide Drugs Market

28. Middle East Constrained Peptide Drugs Market

29. Africa Constrained Peptide Drugs Market

30. Constrained Peptide Drugs Market Competitive Landscape And Company Profiles

31. Constrained Peptide Drugs Market Other Major And Innovative Companies

32. Global Constrained Peptide Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Constrained Peptide Drugs Market

34. Recent Developments In The Constrained Peptide Drugs Market

35. Constrained Peptide Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기